IRIS
PETRONINI, Pier Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.099
AS - Asia 10.153
EU - Europa 7.579
SA - Sud America 1.327
AF - Africa 506
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 5
Totale 31.680
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.823
SG - Singapore 3.548
CN - Cina 2.919
VN - Vietnam 1.586
IT - Italia 1.492
FI - Finlandia 1.151
IE - Irlanda 1.136
BR - Brasile 1.057
SE - Svezia 990
DE - Germania 797
HK - Hong Kong 702
UA - Ucraina 546
FR - Francia 357
ZA - Sudafrica 326
NL - Olanda 299
TR - Turchia 294
BD - Bangladesh 276
GB - Regno Unito 211
IN - India 206
CA - Canada 178
RU - Federazione Russa 160
AR - Argentina 108
AT - Austria 98
BE - Belgio 87
KR - Corea 77
CI - Costa d'Avorio 72
JP - Giappone 70
MX - Messico 60
PL - Polonia 59
IQ - Iraq 58
ID - Indonesia 52
EC - Ecuador 46
PK - Pakistan 44
ES - Italia 43
CO - Colombia 38
CZ - Repubblica Ceca 38
PH - Filippine 38
TH - Thailandia 35
VE - Venezuela 30
IR - Iran 24
LT - Lituania 24
MA - Marocco 24
UZ - Uzbekistan 24
EG - Egitto 22
JO - Giordania 21
SA - Arabia Saudita 20
TN - Tunisia 16
TW - Taiwan 16
KE - Kenya 15
PS - Palestinian Territory 15
AE - Emirati Arabi Uniti 13
EE - Estonia 12
PY - Paraguay 12
AZ - Azerbaigian 11
IL - Israele 11
JM - Giamaica 11
MY - Malesia 11
KZ - Kazakistan 10
PE - Perù 10
AL - Albania 9
CL - Cile 9
DZ - Algeria 9
HU - Ungheria 9
LB - Libano 9
NP - Nepal 9
OM - Oman 9
RO - Romania 9
UY - Uruguay 9
AU - Australia 7
BO - Bolivia 7
LU - Lussemburgo 7
QA - Qatar 7
SY - Repubblica araba siriana 7
CH - Svizzera 6
ET - Etiopia 6
GE - Georgia 6
KG - Kirghizistan 6
MD - Moldavia 6
PA - Panama 5
PT - Portogallo 5
CR - Costa Rica 4
DO - Repubblica Dominicana 4
LV - Lettonia 4
NZ - Nuova Zelanda 4
AM - Armenia 3
BG - Bulgaria 3
BW - Botswana 3
EU - Europa 3
GT - Guatemala 3
HN - Honduras 3
HR - Croazia 3
LK - Sri Lanka 3
NO - Norvegia 3
SI - Slovenia 3
SN - Senegal 3
TT - Trinidad e Tobago 3
AO - Angola 2
BB - Barbados 2
BH - Bahrain 2
BY - Bielorussia 2
Totale 31.645
Salva come PNG Salva come JPEG
Città #
Singapore 1.824
Ashburn 1.310
Dublin 1.133
Chandler 1.092
San Jose 1.038
Dallas 1.020
Santa Clara 690
Beijing 668
Hong Kong 654
Jacksonville 614
Ann Arbor 597
Ho Chi Minh City 472
Parma 464
Dearborn 447
Boardman 370
Hanoi 356
New York 324
Johannesburg 311
Los Angeles 276
Nanjing 264
Izmir 244
Shanghai 232
Princeton 210
Munich 208
Lauterbourg 206
San Mateo 178
Hefei 165
Wilmington 138
Bremen 128
Helsinki 115
São Paulo 108
Chicago 107
Milan 107
Nanchang 98
Toronto 97
Buffalo 96
Council Bluffs 96
Kunming 93
Shenyang 92
Hebei 85
Moscow 83
Vienna 83
Jinan 82
Haiphong 74
Abidjan 72
Woodbridge 72
Brussels 70
Tianjin 65
Frankfurt am Main 64
Da Nang 62
Columbus 58
Des Moines 57
Seattle 56
Bologna 55
Houston 55
Seoul 53
Guangzhou 52
Tokyo 51
Marseille 50
Changsha 49
Turku 49
The Dalles 48
Jiaxing 46
Rome 44
Warsaw 41
Brooklyn 40
London 40
Pune 40
Modena 39
Amsterdam 35
Norwalk 35
Rio de Janeiro 35
Stockholm 33
Düsseldorf 32
Jakarta 32
Denver 31
Montreal 29
Orem 28
Reggio Emilia 27
San Francisco 27
Belo Horizonte 26
Hangzhou 26
Manchester 26
Phoenix 26
Brasília 25
Biên Hòa 24
Redmond 24
Augusta 23
Chennai 23
Fremont 23
Tashkent 23
Zhengzhou 23
Atlanta 22
Hải Dương 22
Baghdad 21
Boston 21
New Delhi 21
Charlotte 20
Dhaka 20
Leawood 20
Totale 19.180
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 350
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 283
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 264
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 251
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 247
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 244
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model 234
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 218
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 215
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 214
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 211
Allotrapianto di polmone sinistro nel coniglio.Modello sperimentale per lo studio della conservazione del polmone. 208
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 208
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 206
Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model 205
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 204
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 203
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 201
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 201
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 201
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 197
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 196
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 193
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 192
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 191
Characterization of gefitinib uptake in NSCLC cell lines 190
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 190
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 190
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 186
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 185
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 185
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 185
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 182
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 182
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 182
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 180
5-benzylidene-hydantoins as new inhibitors of cell proliferation 179
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 178
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 178
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 177
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 176
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 175
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 174
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 174
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 173
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 171
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 171
Left lung allotransplantation in the rabbit. An experimental model for assessment of lung preservation 171
Intrapleural polymeric devices containing Cisplatin for malignant pleural Mesothelioma in a rat tumor model: a preliminary study. 170
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 170
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 170
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma 169
An original application of plasma expanders: heart-lung preservation. 167
Attenuated expression of 70kDa heat shock protein in WI-38 human fibroblasts during aging in vitro 166
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 166
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 165
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 163
Intrapleural adjuvant treatment of mesothelioma : The combination of cisplatin-pemetrexed in rat tumor model 162
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 161
Critical Issues in Assessing Occupational Exposure to Diesel Dust Exhaust 161
Cell culture studies of polysaccharide films loaded with cisplatin for the loco-regional therapy of malignant pleural mesothelioma 161
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 160
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 160
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 160
Methodology for the assessment of lung protection. Human pulmonary artery endothelial cell preservation using haemaccel. 159
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 158
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 158
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 158
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 158
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 158
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 157
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 156
Interaction between occupational radon exposure and tobacco smoke: a systematic review 155
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 155
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 155
Adaptive cellular response to osmotic stress in pig articular chondrocytes 154
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 153
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 151
An effective solution for prolonged preservation of cultured human pulmonary artery endothelial cells 150
Anti-proliferative and pro-apoptotic effects of soarfenib in MCF-7/AROM-1 breast cancer cells. 149
Mannich base derivatives as novel EGFR irreversible inhibitors 149
SiO2/SiC core-shell nanowires for nanomedicine applications 149
) Sperimentazione su pneumociti di tipo II per la conservazione del polmone in funzione del trapianto. Soluzioni idroelettrolitiche a confronto. 147
Synergistic activity of letrozole and sorafenib on breast cancer cells 147
A new extracellular type solution for lung preservation: "in vitro" comparison with Beltzer, low potassium Dextran and Euro-Collins solutions by means of human lung fibroblasts. 147
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 147
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 147
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 147
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 146
Alterazioni della degradazione proteasoma-dipendente nel corso dell'invecchiamento ed effetti delle restrizioni caloriche 146
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 146
New MDR1 inhibitors for overcoming multidrug resistance 146
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 145
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 145
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 145
Alterazioni della degradazione proteasoma-dipendente nel corso dell’invecchiamento ed effetti delle restrizioni caloriche 145
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 145
Induction of betaine/gammabutyric acid transport activity in chondrocytes exposed to hypertonicity 144
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 144
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 144
Totale 17.707
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.689
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 105.689
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202161 0 0 0 0 0 0 0 0 0 0 0 61
2021/20221.057 49 33 48 65 26 12 141 131 62 76 74 340
2022/20234.288 422 456 285 283 433 470 39 274 1.376 28 170 52
2023/20241.843 88 141 59 50 151 456 133 141 65 96 160 303
2024/20255.752 190 298 368 406 555 618 313 236 778 500 510 980
2025/202612.154 1.111 1.163 1.531 1.111 1.610 662 1.300 377 1.658 910 475 246
Totale 31.995